1. Home
  2. HQ vs FLGT Comparison

HQ vs FLGT Comparison

Compare HQ & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$12.22

Market Cap

499.5M

Sector

N/A

ML Signal

N/A

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$15.94

Market Cap

525.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQ
FLGT
Founded
2018
2011
Country
Singapore
United States
Employees
44
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.5M
525.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
HQ
FLGT
Price
$12.22
$15.94
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$28.33
AVG Volume (30 Days)
229.2K
512.2K
Earning Date
05-05-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,730,000.00
Revenue This Year
N/A
$10.09
Revenue Next Year
N/A
$12.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$13.46
52 Week High
$14.22
$31.04

Technical Indicators

Market Signals
Indicator
HQ
FLGT
Relative Strength Index (RSI) 56.65 51.68
Support Level $9.08 $15.39
Resistance Level $12.70 $16.70
Average True Range (ATR) 1.11 0.67
MACD 0.17 0.14
Stochastic Oscillator 80.29 74.59

Price Performance

Historical Comparison
HQ
FLGT

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Share on Social Networks: